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 Chronic kidney disease (CKD) is common. A small propor-
tion of patients with CKD progress to require interventions, 
which may include dialysis. Monitoring patients with CKD is 
supported by national guidelines. Monitoring systems to plan 
management of CKD vary in form. A novel monitoring system, 
the virtual CKD clinic (VC) was introduced at our hospital. The 
VC is a non-face-to-face results review of patients with CKD. 
We found that the VC was an effective monitoring system. 
None of the patients from the VC required emergency dialysis, 
suggesting robust surveillance. Survival was similar to patients 
with CKD discharged to primary care. 
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 Introduction 
 Chronic kidney disease (CKD) is common in the UK with estimates 
of prevalence for all CKD (stage 1 to 5) of 14% in males and 13% 
in females. Late stage CKD (stages 4 and 5) is estimated at 6%. 1 
The incidence of CKD increases with age and comorbidity. The 
most frequent causes of dialysis-dependant CKD in the UK are 
diabetes, hypertension, and vascular disease. 2 A small proportion 
of patients with CKD will progress to require renal replacement 
therapy. 3 
 Systems of surveillance for patients with CKD vary depending 
on local practice. Most of the surveillance occurs face-to-face 
in primary care or in hospital outpatients. The objectives of 
surveillance of CKD is to arrange timely preparation for renal 
replacement therapy and to avoid unplanned emergency 
dialysis, which is associated with worse survival, 4 or to prepare 
for palliative non-dialysis care. Variation in incidence rates of 
unplanned dialysis is wide. 5 A number of mechanisms have been 
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proposed in order to improve surveillance for advancing CKD and 
improve outcomes. 
 In the UK in 2006 the Royal college of Physicians (RCP) and 
the Royal college of General Practitioners (RCGP) published 
comprehensive guidance on the management of CKD. 6 The 
RCP guides adopted the US 2002 National Kidney Federation 
Kidney Disease Outcomes Quality Initiative (NKF KDOQI) CKD 
classiﬁcation system and management guidelines. 7 
 The 2006 RCP/RCGP CKD guidelines proposed a collaborative 
approach between primary and secondary care for surveillance 
and management of CKD. The guidelines propose a ‘virtual 
nephrologist’ model of care, stating that 
 There are important options for computerised decision 
support including the virtual nephrologist model, which requires 
computerised transfer of information including laboratory 
measurements, between the GP surgery, the local laboratory and 
the nephrology service, and division of responsibility for acting on 
such results clearly identiﬁed in the care plan . 
 The guidelines were not speciﬁc on the deﬁnition of the virtual 
nephrologist. In our renal unit virtual CKD clinics (VCs) were 
proposed as a mechanism for improving monitoring of CKD. Our 
VC model was designed to utilise information technology (IT) 
and computer-based systems and therefore could be regarded as 
computerised decision support system (CDSS) for CKD monitoring. 
While strongly reliant on IT, the design of the VC had consultant-
led decisions and review at the core of the process. 
 The 2006 RCP guide has since been superseded by the National 
Institute for Health and Care Excellence (NICE) guidelines on CKD 
2014. 8 
 CDSSs have been deﬁned as computerised software systems 
designed to assist clinicians with decision-making tasks. 9 Uptake 
of novel systems and proof of concept can be very slow in health 
systems. Some sources state that the time between demonstrated 
beneﬁt of an innovation and widespread introduction of the 
innovation to be 17 years. 9 Further subtypes of CDSS have 
been described. Systems can be passive (users explicitly make a 
request for support), semi-active (watchdog systems are invoked 
automatically and present information when users request it) or 
active (triggered automatically, present information without it 
being requested and, in some cases, make decisions without the 
intervention of clinicians). The VC model developed in our unit is 
an active form of clinical decision support system (CDSS). 
 A number of forms of CDSS for CKD management have been 
described. Abdel-Kader  et al conducted a trial of a passive alert 
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 The VC was developed with full support and knowledge of 
primary care. The availability of the VC was publicised in a series of 
lectures, discussions and visits primary care practices in the region. 
The VC was supported by the hospital trust with IT support, nurse 
practitioner assistance and dedicated consultant time. 
 As part of the VC ‘package’ primary care was offered a ‘hotline’ 
phone number to allow access to consultant advice for questions 
about patients with CKD. The consultant sessions also provided 
rapid access for patients requiring review when returning to face-
to-face consultant clinic from the VC. 
 The VC was initiated according to national guidelines (RCP/RCGP 
CKD guidelines 2006) for local service development and service 
improvement. Ethical approval was not required as this service 
development conformed to national guidelines. 
 Patients were scheduled to have regular non-face-to-face test 
result reviews in the month after each test using the electronic 
pathology reporting system. Patients and their primary care 
doctors were informed of the outcome of the review by structured 
letter. 
 One of the following outcomes or actions was chosen based on 
the results. 
 > Repeat tests at standard frequency according to the CKD 
guidelines with subsequent non face-to-face review. 
 > Repeat test at shortened interval (if deterioration suspected) 
with subsequent non-face-to-face review. 
 > Recall for face-to-face review in conventional clinic. 
 > Reminder letters were sent if the patient had failed to have the 
required blood tests. 
 > Discharge (if another signiﬁ cant life-limiting disease diagnosed). 
 > Deceased / receiving palliative care. 
 The patient and primary care letter contains results (eGFR, Hb, 
urine protein:creatinine ratio) and includes blood and urine test 
forms for the next review. The review date was included in the 
letter. 
 Failure to undergo testing was followed by a structured 
reminder letter. Failure to undergo testing after three reminders 
was interpreted as a loss to follow-up. This was accompanied 
by a letter to the patient and to the primary care practice. 
Discussion with primary care physician was conducted if the 
patient was felt to be at risk (eg advanced stage CKD or known 
comorbidity). 
 The VC is based on human-led decision making and as such 
clinical opinion was also considered when movement between 
virtual and hospital care was undertaken. Some knowledge of 
the patients, their records and other elements such as records of 
unplanned attendances were available to inform the decisions. 
Utilisation of a renal database (Clinical Computing PROTON ®) and 
a graphical function on the pathology reporting system (Sunquest 
ICE ® ) were also considered. 
 Deterioration in tests was said to be present if: 
 > a deterioration of estimated glomerular ﬁ ltration rate (eGFR) of 
greater than 5 mL/min/12 months 
 > the arrival of patient at CKD stage 4 when further deterioration 
was thought to be likely 
 > recurrence or development of proteinuria 
 > progression of urine protein to creatinine ratio to levels over 100 
mg/mmol 
 > communication from patient or primary care doctor regarding 
symptoms. 
based system of alerts for patients with CKD 3 and 4 in primary 
care. 10 A non-signiﬁcant increase in the rate of proteinuria testing 
was seen but failed to increase referrals or use of angiotensin-
converting-enzyme (ACE) inhibition. No other outcomes were 
reported. They hypothesised that little improvement occurred 
because of the preceding change to eGFR testing which had 
increased surveillance and referral for CKD patients from primary 
care physicians. Other projects have demonstrated considerable 
beneﬁts of surveillance coupled with education. Rayner  et al 
improved vascular access at the start of dialysis and improved 
end-of-life care with a broad-ranging community-wide CKD 
management project. 11 
 The beneﬁt of CDSS in this context has not been demonstrated 
convincingly for clinical outcomes such as survival or proportion of 
patients having unplanned dialysis. 
 The published literature shows a proliferation in the number 
type and intention of computerised systems to aid decisions and 
chronic health care and kidney disease. 12 A variety of information 
technology platforms have been utilised in the assistance of 
managing CKD. Education, drug adherence and reconciliation and 
lifestyle advice are frequent themes. The iNephro project examined 
the use of a smartphone app to encourage drug adherence in 
patients with CKD. 13 A large number of downloads (over 11,000) 
were followed by rapid decline in use, less than 10% by 1 year. 
 The aim of our VC is to provide and ensure a robust monitoring 
system for patients with CKD using non-face-to-face computer-
based decision support with the intention of improving recognition 
of patients with deteriorating CKD, initiation of appropriately 
timed interventions and reduction of late presentation. 
 Methods 
 The Southend Renal Unit provides adult renal services to a 
population of approximately 330,000 people in south east Essex, 
UK. 
 The Southend Virtual Renal Clinic (VC) was commenced in 
2006 following the publication of the RCP/RCGP guidelines on the 
management of CKD. 
 Selection criteria for the VC: 
 > non-progressing or stable CKD 
 > capacity to understand and adhere with the VC monitoring 
requirements 
 > absence of other reasons to mandate conventional follow-up 
(eg active comorbidities). 
 The RCP/RCGP CKD guidelines 2006 deﬁne progression as a 
reduction in eGFR of greater than 5 mL/min/year. All patients 
transferred to the VC had the monitoring process described and 
explained face-to-face by a consultant physician in a conventional 
clinic setting. On the point of transfer to VC, return to face-to-
face clinic criteria were discussed with the patients. The prompt 
availability of return to conventional face-to-face review clinic was 
emphasised at the discussion of transfer to VC. 
 All patients discharged from the single clinic that were eligible 
were offered VC follow-up. Patients ineligible (eg eGFR decline over 
5 mL/min/1.73 m 2 /year or other reason) remained in conventional 
face-to-face follow-up. 
 On entry to the VC, patients were given blood (electrolytes and 
creatinine) and urine (urine protein:creatinine ratio) test request 
forms. Patients were instructed to have their tests 1 month prior to 
the date of the review. 
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 Comorbidities 
 Common comorbidities (peripheral vascular disease, coronary 
disease, cerebrovascular disease, diabetes, chronic obstructive 
pulmonary disease [COPD], hypertension and malignancy) were 
recorded as present when documentary evidence was seen in the 
electronic record. 
 Sample collection 
 A robust system of community phlebotomy and pathology sample 
retrieval was in place in the region. All samples (community or 
hospital) were processed by the same laboratory at Southend 
Hospital and results were stored on a single pathology system 
(Sunquest integrated clinical environment, ICE) that provided data 
to both primary and secondary care. Retrieval of laboratory results 
was robust and reliable. 
 Data collection 
 Electronic patient records (patient administration system [PAS®], 
integrated clinical environment [ICE®]) were used to collate 
clinical, comorbidity, demographic and laboratory data for all 
patients in the VC from July 2006 to March 2015. 
 Outcomes 
 The outcome measures were recorded included patient survival, 
requirement for renal replacement and unplanned emergency 
dialysis. Measurements of process included frequency of 
monitoring of relevant tests compared to guidelines. 
 Survival data regarding patients discharged to primary care 
from a conventional renal clinic in the same department under 
a different nephrologist were retrieved. Patients from this clinic 
with stable CKD were discharged to primary care with instructions 
for monitoring according to the RCP/RCGP guidelines. Survival 
rates in the VC were compared to survival rates in the VC using 
a chi-squared method to test the hypothesis that there was no 
difference in survival between groups. 
 Diagnoses, comorbidities and outcomes were retrieved from 
electronic records and HES data (Hospital Episode Statistics – NHS 
Digital). 
 Results 
 A total of 683 patients were reviewed in the VC between July 2008 
and March 2015. Over this period, 5,024 non-face-to-face ‘virtual’ 
reviews were conducted. 
 Forty-ﬁve percent were female. The median age at ﬁrst review 
was 78.5 years (range 17–90). Nine percent were under 40 years 
old; 43% between 40 and 75 years old and 48% over 75. Table 1 
shows the number of patients in each CKD stage at entry to the VC. 
Mean eGFR on entry to VC was 41.3 mL/min (standard deviation 
[SD] = 25). At entry the average stage of CKD was stage 3. 
 Seventy-six percent were over 60 years old. The mean duration 
of monitoring for a patient in the VC was 42.5 months (SD = 30 
months). 
 Primary renal diagnosis of patients in the VC 
 The majority of patients (72%) were diagnosed as chronic renal 
disease of uncertain aetiology (494 patients in total). 
 Forty-six patients were diagnosed with renovascular disease 
(7%). Thirty-eight had diabetic nephropathy (5%) out of 111 
with diabetes (16%). Twenty-nine patients had polycystic kidney 
disease (4%). 
 Comorbidities of patients in the VC 
 Hypertension was present in 318 patients (47%). Ischaemic heart 
disease was present in 122 (18%). 
 Peripheral vascular disease was present in 47 patients (7%) with 
cerebrovascular disease in 59 (9%). A diagnosis of malignancy was 
present in 68 patients (10%). COPD had been diagnosed in 34 (5%). 
 Atrial ﬁbrillation was present in 41 patients and aortic stenosis or 
valve replacement in 15; dementia was diagnosed in 18; gout was 
present in 36 patients; congestive cardiac failure in 16. 
 Comorbidity burden 
 The presence of the most frequent comorbidities was recorded; 
this consisted of hypertension, ischaemic heart disease, peripheral 
vascular disease, malignancy, stroke, diabetes and COPD. The 
burden of comorbidity by patient numbers is shown in Table 2. 
Only 248 patients had no recorded comorbidities. Most patients 
had between one and three comorbidities. 
 Cardiovascular comorbidity 
 388 of 683 (57%) patients had one or more cardiovascular 
comorbidities while 196 patients had two or more (28%). 60 
patients had three or more cardiovascular comorbidities (9%). 
 Monitoring 
 The annual frequency of testing for CKD patients was recorded 
and compared to the recommended test frequency from the 
RCP and RCGP guidelines (see Table 3). Overall, patients received 
testing more frequently than the recommended guidelines. 
 Outcomes 
 Survival 
 By March 2015, 218 patients had died. The average age at death 
was 81-years-old (SD = 9.4 years). Mean duration of VC follow-up 
was 28.4 months. 
 Survival in patients with standard care compared to VC 
(see Table 4) 
 Survival data on patients reviewed in the VC was compared to 
standard care (patients discharged from a general renal clinic 
in the same unit that were followed up in general practice). 
Of patients in the VC, 31.9% had died by the end of the data 
collection period. When compared to the proportion of patients 
surviving after discharge to general practice according to 
guidelines, no signiﬁcant difference in survival rates was apparent 
at individual stages. A survival beneﬁt for the VC compared to 
standard care was apparent over all stages of CKD combined. 
 Patients from the VC going on to require renal replacement 
therapy (see Table 5) 
 Twenty-seven patients required renal replacement therapy; 26 
had dialysis and one had a preemptive renal transplant. Nineteen 
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patients had haemodialysis and seven had peritoneal dialysis. 
Twenty patients out of 26 started dialysis with deﬁnitive dialysis 
access; six had semi-permanent dialysis lines. One patient 
required urgent placement of the line. No temporary dialysis 
catheters were used and no out-of-hours / emergency dialysis was 
required. 
 Discussion 
 This article describes the patient characteristics and outcomes 
of the VC, a computer-assisted non-face-to-face CKD monitoring 
system. 
 The spectrum of age, severity and comorbidity in our VC is 
similar to that found in published data from other developed 
countries. 14 
 No signiﬁcant difference in survival was demonstrated for the 
different stages of CKD. Overall survival was better in the VC than 
standard care. The difference reaches statistical signiﬁcance, 
but clinical signiﬁcance is less clear. This study retrieved the data 
in retrospect. The data is observational and not a randomised 
comparison and as such the inference of a survival beneﬁt has only 
limited strength. 
 Twenty-seven patients required renal replacement therapy. All 
of the patients emerging from the VC and going on to need renal 
replacement therapy did so in a planned and controlled manner. 
Unplanned start for dialysis is said to occur in patients with CKD 
that are started on dialysis as an emergency. It is also colloquially 
referred to as ‘crash landing’. There were no late presentations 
‘dialysis crash landers’ from the VC.  
 A high proportion of patients had good quality of access (ﬁstula 
or peritoneal dialysis [PD] catheter) when starting dialysis from 
VC. The rates for ﬁstula formation and PD catheter placement in 
patients from the VC were higher than the in the region and the 
national average, see Table  6 (data from renal registry multisite 
access audit 2014 2 ). 
 The 2006 KDOQI guidelines suggest that ‘patients should have a 
functional permanent access at the initiation of dialysis therapy’. 7 
No consensus deﬁnition of unplanned dialysis exists. 
 The renal registry record access type of in the UK multisite 
dialysis access audit 2015. 5 Use of non-tunnelled lines in patients 
with CKD requiring dialysis is a surrogate marker for unplanned 
dialysis. The rates of non-tunnelled line use are highly variable 
across the UK. Late referral to renal services is considered as 
a factor contributing to the proportion of patients having 
suboptimal access. Patients receiving dialysis via non-tunnelled 
lines despite being known to renal services is also a marker of 
unplanned dialysis. 
 Other deﬁnitions or markers of unplanned dialysis have been 
suggested. Brown  et al deﬁned unplanned dialysis as starting 
chronic dialysis as an inpatient. 15 In their retrospective analysis 
unplanned dialysis was associated with diabetes, heart failure and 
high body mass index. Absence of predialysis education was also 
found to be associated with unplanned start in addition to medical 
comorbidity. 
 Buck  et al deﬁned classiﬁed unplanned start as ‘known acute 
patients’ that had been encountered by renal services for over 4 
months prior to starting dialysis as an emergency. 16 Unplanned 
dialysis is strongly associated with poor survival following initiation 
of renal replacement therapy (RRT). 17 Kessler  et al found a strong 
relationship for length of time between referral and initiation 
of RRT and short-term survival after RRT. 18 In 2015, 13.9% of 
patients known to UK renal services for more than 90 days started 
haemodialysis in this cohort did so with a non-tunnelled line. 
 Initial access for patients starting dialysis 
 Our of 19 patients starting haemodialysis from the VC, 13 started 
with a functioning arteriovenous (AV) ﬁstula (68%). 
 Renal Association guidelines state that 65% of patients 
commencing haemodialysis should start with an AV ﬁstula. 19 There 
is wide regional variation with lower than 15% ﬁstula rate seen in 
some centres. Only ﬁve centres in the UK achieved the target of 
65% of patients starting dialysis with an AV ﬁstula. The national 
audit report accepts that the data do not explain the reasons for 
the wide variation in attainment of the target. 
 Referral time has a strong inﬂuence on the type of starting 
access for both PD and haemodialysis. 20 Buck  et al also found that 
a strong predictor for starting with deﬁnitive access was attending 
predialysis clinics. 16 Patients who did not attend a predialysis clinic 
had a 90% increase in the odds of having an urgent known acute 
dialysis initiation. 
 Patients with polycystic kidney disease (PKD) have a more 
predictable course of deterioration in renal function and had the 
highest chance of starting haemodialysis with a ﬁstula (66.1%). 
PKD patients are also more likely to be known to renal services. 
 Patients with PKD represented 4.5% of the total number 
of patients starting dialysis and 3.8% of those starting on 
haemodialysis in the UK. 2 In the VC population, 29 of 693 patients 
(4.2%) had PKD. PKD is not over-represented in the VC; therefore, it 
is not an explanation for the low incidence of crash landing. 
 Non-linear progression of renal disease and abrupt changes 
due to intercurrent illness contribute to the challenge in preparing 
patients at an appropriate time for renal replacement. The 
consequences for patients of late presentation are severe 
and include a reduced survival on dialysis. Therefore, robust 
 Table 1.  Number of patients by chronic kidney 
disease (CKD) stage at entry to the virtual clinic 
(VC) 
CKD stage at entry to VC Number of patients 
CKD stage 1 40
CKD stage 2 72
CKD stage 3 300
CKD stage 4 237
CKD stage 5 25
 Table 2.  Burden of comorbidity by patient numbers 
Comorbidities per patient Number of patients 
0 248
1 200
2 143
3 156
4 18
5 5
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surveillance systems are important in an attempt to produce a 
consistent approach to the reduction of poor outcomes in this 
small but important group. The VC may represent a scalable and 
transferrable technique that could contribute to reducing the 
occurrence of unplanned dialysis. 
 Other large-scale and important studies continue to investigate 
the beneﬁt of virtual CKD monitoring. The ASSIST-CKD project 
is a UK-wide study sponsored by Kidney Research UK to ‘spread 
eGFR graph surveillance for the early identiﬁcation, support and 
treatment of people with progressive chronic kidney disease’. 21 
The project involves 20 renal centres in the UK with the objective 
of identifying those patients at greatest risk of progression in order 
to deliver more timely treatment. This large and well-designed 
project will further clarify the role of surveillance and improve the 
ability of clinicians to add value to the CKD patient journey. 
 Just over 4% of the patients in the VC went on to receive RRT 
demonstrating that RRT requirement is a rare event in this group. The 
VC is intended as a surveillance technique and as such could be said 
to be effective. A technique that further reﬁnes and improves the 
predictive process is clearly felt to be desirable by the ASSIST CKD 
group and the wider nephrology community. 
 Almost one-third of patients died during the period of 
observation (32%). The Rayner study demonstrated a great 
beneﬁt in that a large proportion of patients receiving palliative 
care died out of hospital. 11 The data from the VC did not 
include place of death or involvement of palliative care services. 
Modiﬁcations to the VC process could include this element of care 
and could add more value to non-face-to-face surveillance. 
 The VC is less resource intensive than face-to-face clinics. It 
circumvents the need for patients to travel to the hospital for a 
face-to-face review of tests, permitting less disruption to work 
schedules and less inconvenience for patients, particularly those 
with other comorbidities. It may represent an additional tool 
to extend contact with renal patients in a cost-efﬁcient way, 
which encourages participation and adherence. High levels of 
acceptance and participation may be attributable to the ﬂexibility 
of timing of tests, the convenience of the local infrastructure and 
the reminder system that is integral to the process. 
 The observed frequency of blood tests in the VC exceeds that 
of the frequency recommended in the guidelines. The 2006 Joint 
RCP and RCGP Guideline Development Committee (GDC) speciﬁed 
a frequency of testing dependent on stage of CKD. 
 This was based on consensus and accompanied by a statement 
that frequency of testing should be adjusted according to clinical 
judgment. Recommendation 9 from the guidelines states
 … exact frequency should depend on the clinical situation. 
The frequency of testing may be reduced if the eGFR levels 
remain very stable but will need to be increased if there is rapid 
progression. 
 Table 3.  Annual frequency of monitoring in the virtual clinic (VC) compared to Royal College of Physicians / 
Royal College of General Practitioners guidelines and National Institute of Health and Care Excellence 
guidelines 2014 
   NICE 2014  
eGFR CKD Stage RCP/RCGP 2006 ACR <3 ACR 3–30 ACR >30 Frequency of VC tests 
>90 1 1 <1 1 >1
60–89 1 1 <1 1 >1 2.27
45–59 2 1 1 1 2 2.77
30–45 3 2 <2 2 >2 4.35
15–30 4 4 2 2 3 6.38
<15 5 8.6 4 >4 >4 10.8
 Observed VC monitoring frequency compared to frequency of monitoring of chronic kidney disease according to stage (NICE guidelines 2008 adopt the same advice 
as RCP/RCGP guidelines 2006. NICE 2014 based on KDIGO 2012 guidelines changed the recommended frequency of testing and included level of albuminuria as a 
factor. ACR = albumin to creatinine ratio mg/μmol 
 Table 4.  Survival of patients in in the virtual clinic (VC) compared to patients with chronic kidney disease 
(CKD) discharged to primary care according from the conventional renal clinic (RC) to CKD stage 
CKD stage VC alive Total RC alive Total VC alive (%) RC alive (%) df, number χ2 value p value 
1 36 41 4 4 87.80 100 (1, n = 45) 0.55 0.46
2 76 86 5 7 88.37 71.42 (1, n = 93) 1.65 0.2
3 195 262 34 46 74.42 73.91 (1, n = 308) 0.01 0.94
4 125 209 55 89 59.80 61.79 (1, n = 298) 0.1 0.74
5 33 85 33 71 38.82 46.47 (1, n = 156) 0.92 0.33
 Total 465 683 131 217 68.08 60.36 (1, n = 900) 4.38 0.036
 df = degrees of freedom 
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 NICE CKD guidelines 2008 clinical guideline 73 adopted the 
same recommendations for frequency of testing as the RCP 2006 
guidelines. 
 Revision of the NICE CKD guidelines in 2014 adjusted the 
advice to increase frequency of testing where depending on the 
urinary albumin excretion levels. The guidelines were published 
in July 2014. The data set considered in this study concluded in 
March 2015. Changes in monitoring frequency recommended in 
these guidelines did not affect the patients in this data set. 
 The 2014 guidelines discuss at appropriate length the 
frequency of testing and the number of factors associated with 
progression and outcome. The non-linearity of progression 
of CKD is emphasised, with advice regarding the signiﬁcance 
of increases and decreases to eGFR of 25% associated with 
increase mortality risk. The guidance also states the importance 
that the clinician and patient recognise that changes in the 
plus or minus 25% range can be explained by error and natural 
variability. The frequency of testing is derived from the 2012 
KDIGO guidelines, which in turn are based on expert opinion. 
They go on to state  
 There are many who would like more deﬁnitive guidance on 
frequency of measurement according to speciﬁc categories of 
risk. However, this is not possible at the current time given the lack 
of evidence to guide such statements and the extreme number 
of individual circumstances that would mitigate any proposed 
protocol. 22 
 Adherence to requests for blood sampling was very high. 
Patient engagement in the VC is high. The regional phlebotomy 
infrastructure allows for convenient blood sampling and may 
facilitate participation and adherence to VC surveillance. 
 Virtual clinics in other centres 
 Early models of virtual renal clinics were acknowledged and 
promoted in a report by a joint working party by the RCP and the 
NHS Alliance in 2004.  Clinicians, services and commissioning in 
chronic disease management in the NHS: The need for coordinated 
management programmes 23 offers a deﬁnition of chronic disease 
management programmes based on the Wagner 24 model. 
The model describes a pathway to improved chronic disease 
management by the development of better self-management, 
clinical information systems, delivery system redesign, decision 
support, healthcare reorganisation and improved community 
resources. It also describes the implementation and delivery of 
chronic disease management programmes giving six examples of 
programmes from the UK. 
 The Southampton Integrated Monitoring of Nephrology 
(SIMON) 25 programme evaluated a CDSS that facilitated 
monitoring of patients with CKD. The programme involved 
shared care between general practice and hospital-based 
clinicians. Following an initial assessment visit, a nephrologist 
sees and advises on blood test results and blood pressure 
measurements without seeing the patient face-to-face. The 
SIMON scheme enables remote monitoring by nephrologists of 
patients with CKD, with computer-generated reminder letters to 
prompt regular follow-up. A retrospective case control technique 
was used. In addition to monitoring, some interventions to 
improve blood pressure by remote/home measurement showed 
an improvement in the intervention group. The system proved 
feasible with high levels of patient participation and adherence. 
Importantly it demonstrated a system that shared care was of 
beneﬁt and feasible. There is reference in the RCP guidelines 
to the SIMON system, which is described as a development of 
virtual services. 
 Data on survival in patients with CKD that had not been referred 
to secondary care was published by Stevens  et al. 14 The study 
included patients with a creatinine level of >180 μmol/L for men 
and >135 μmol/L for women. This equates to an estimated GFR 
of 35 mL/min by modiﬁed Modiﬁcation of Diet in Renal Disease 
calculation. The patient population were from east Kent, UK and 
 Table 6.  Rates of tunnelled lines, fistulas and pre-emptive transplants in patients requiring renal replacement 
therapy (RRT) from the virtual clinic compared to regional and national averages and UK best and worst 
performances (UK renal registry data 5 ) 
  VC (2006-15) (%) Region 2015 (%) UK average 2015 (%) UK best 2015 (%) UK worst 2015 (%) 
Non-tunnelled line 0 23.8 13.9 0 32.7
Tunnelled line 22.2 19 26.2   
Fistula/graft 48 33.3 36.6 61.9 14
Peritoneal dialysis 37 23.8 23.4 55.6 0
Pre-emptive transplant 3.7 5 7.5   
Total (N) 27 21 4050   
 Data for patients known for more than 90 days 
 Table 5.  Number of patients starting renal 
replacement therapy (RRT) from the virtual clinic 
according to starting modality 
Starting modality Number of patients 
Pre-emptive transplant 1
Peritoneal dialysis 7
Haemodialysis 19
Primary fistula 13
Tunnelled line 6
Temporary line 0
Urgent dialysis out of hours 0
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were predominantly white (2001 census data showing that less 
than 1.3% coming from an ethnic minority). 
 The average age was 83-years-old and during a mean average 
of 31.3 months of follow-up nearly 40% of the study population 
had died. 
 Drey  et al reported a retrospective cohort study of 1,076 patients 
with CKD in the Hampshire area of the UK in 2003. 26 The survival 
in all groups with CKD (creatinine of 1.7 mg/dL or 150 μmol/L) was 
found to be 31% after a mean average follow up of 5.5 years. 
Thirty-nine patients required renal replacement therapy. 
 Ennis  et al reported the effect of appending alerts to laboratory 
reports to physicians in a case control study. 27 The endpoints 
measured were the frequency of blood test relating to CKD and 
their adherence to recommended test frequencies in guidelines 
(KDOQI/KDIGO) The tests include eGFR, parathyroid hormone, 
phosphate and other regularly tested analytes. The study covered 
large numbers of patients and practices; 12,353 subjects and 
42,996 controls. Decision system reports did increase adherence 
to guidelines and was considered beneﬁcial. The study was of 
short duration (0.73 years mean follow-up) and no clinical hard 
endpoints were considered. 
 No penalties were recorded for over-testing. No measurement of 
effect of false alarm or inappropriate activity generated by reports 
were considered. 
 The authors conclude that there were beneﬁts of the simplicity 
of integration and scalability of their CDSS were its strengths but 
also emphasised that guideline authors may need to take these 
developments into consideration. 
 Signiﬁcant effects have been demonstrated in previous 
studies. Rayner  et al have demonstrated an improvement the 
treatment pathway going to palliative care and in local rates of 
starting dialysis on ﬁstula or peritoneal dialysis associated with 
surveillance. 11 
 National scale studies are also currently underway to explore the 
beneﬁts of electronic surveilance. 21 
 Unlike this study, no virtual CKD systems have demonstrated 
measurable beneﬁt on the clinical endpoint of access quality when 
compared to local practice. 
 Conclusions 
 The virtual CKD clinic described here is a robust system for follow-
up of patients with CKD. It is associated with good adherence 
from patients. 
 The low level of unplanned dialysis appears to be its main 
advantage. 
 As a pilot study it has the beneﬁt of a long-term follow-up 
(7 years). It is a system that relies on standard infrastructure and 
could be reproduced and ’up-scaled’ in locations where rates of 
unplanned dialysis exceed the expected or average national level. 
There appears to be no survival disadvantage when compared to 
conventional guideline-based primary care. The success may also 
be due to the incorporation of a human element in the decision-
making pathway and the capacity to promptly recall patients to 
face-to-face hospital care. ■ 
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